

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 14

[Docket No. 00N-1634]

JMB

Display Date	4-20-01
Publication Date	4-23-01
Certifier	SREESE

Public Hearing Before a Public Advisory Committee; Examination of Administrative Record and Other Advisory Committee Records; Withdrawal

AGENCY: Food and Drug Administration, HHS.

ACTION: Direct final rule; withdrawal.

SUMMARY: The Food and Drug Administration (FDA) published in the **Federal Register** of January 8, 2001, a proposed rule (66 FR 1276) and a direct final rule (66 FR 1257) to amend FDA regulations governing the public disclosure of written information for consideration by an advisory committee at an advisory committee meeting. The comment period closed March 26, 2001. FDA is withdrawing the direct final rule because the agency received significant adverse comment.

EFFECTIVE DATE: The direct final rule published in the **Federal Register** of January 8, 2001 (66 FR 1257), is withdrawn effective [*insert date of publication in the Federal Register*].


FOR FURTHER INFORMATION CONTACT: Andrea C. Masciale, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

cd0180

NWLI

Therefore, under the Federal Food, Drug, and Cosmetic Act, and under the authority delegated to the Commissioner of Food and Drugs, the direct final rule published in the **Federal Register** of January 8, 2001 (66 FR 1257), is withdrawn.

Dated: April 17, 2001
April 17, 2001.




Ann M. Witt,
Acting Associate Commissioner for Policy.

[FR Doc. 01-????? Filed ??-??-01; 8:45 am]

BILLING CODE 4160-01-S

CERTIFIED TO BE A TRUE
COPY OF THE ORIGINAL



Syzette N. Reese